The incidence of serious complications after selective laser trabeculoplasty
- PMID: 40515629
- PMCID: PMC12803589
- DOI: 10.1111/aos.17536
The incidence of serious complications after selective laser trabeculoplasty
Abstract
Purpose: To evaluate the incidence of serious complications after selective laser trabeculoplasty (SLT).
Methods: All patients who underwent SLT at the Department of Ophthalmology, Helsinki University Hospital, were eligible for the study from 1 January 2012 to 31 December 2018. Data regarding patients' demographics, procedure details, complications, predisposing factors and clinical outcomes were extracted retrospectively from electronic medical records. The primary outcome measures were serious complications, including corneal oedema, corneal scarring, hyperopic shift, synechia, anterior chamber bleeding and hyphema.
Results: A total of 6081 SLTs (4601 eyes) of 2812 patients were analysed. Twelve patients had bleeding in the anterior chamber angle (incidence 2/1000 SLT laser treatments), and four of them developed hyphema (incidence 0.7/1000 SLT laser treatments). Corneal oedema or Descemet's membrane folds were reported in six treated eyes, resulting in an incidence of 1/1000. One myopic eye had a permanent corneal scarring, thinning and irregular astigmatism with a hyperopic shift (5.3 D with recovery to 1.25 D in three years), resulting in poor visual acuity (from preoperative 0.9 to 0.4 at the last control). The incidence was less than 0.2/1000 for all SLT treatments (95% CI ≤0.1 to 1.0) and 1/648 for SLT laser treatments in high myopia (spherical equivalent ≤-5.00 D).
Conclusions: After SLT, the number of complications was low, with only one permanent vision deterioration after 6081 treatments. These findings may help clinicians reassure patients about SLT safety when offering SLT as a first-line treatment for ocular hypertension or open-angle glaucoma.
Keywords: complication; glaucoma; hyperopic shift; hyphema; selective laser trabeculoplasty.
© 2025 The Author(s). Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
Conflict of interest statement
Eeva S. Ojanen has received lecture fees from Santen Finland and congress expenses from AbbVie Finland. Joni A. Turunen has received lecture fees from Thea Finland and Santen Finland. He has served on the advisory board of Novartis Finland and as a consultant for Maculaser Oy. Mika Harju has received lecture fees from Thea Finland and Santen Finland. He has served on the advisory board of Allergan. All are unrelated to this work.
References
-
- Dahlgren, T. , Ayala, M. & Zetterberg, M. (2024) Optimal performance of selective laser trabeculoplasty: results from the Swedish optimal SLT multicenter randomized controlled trial. Ophthalmol Glaucoma, 7, 105–115. - PubMed
-
- European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition . (2021) British Journal of Ophthalmology, 105, 1–169. - PubMed
-
- Gazzard, G. , Konstantakopoulou, E. , Garway‐Heath, D. , Adeleke, M. , Vickerstaff, V. , Ambler, G. et al. (2023) Laser in glaucoma and ocular hypertension (LiGHT) trial: six‐year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology, 130, 139–151. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
